CAB

BioAtla to Participate in the Citizens JMP Life Sciences Conference

Retrieved on: 
Mercredi, mai 8, 2024
Citizenship, Therapy, Conference, SAN, CAB, Conditional

SAN DIEGO, May 08, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that the Company’s management will participate in a fireside chat and one-on-one investor meetings at the Citizens JMP Life Sciences Conference, to be held in New York, NY May 13-14, 2024.

Key Points: 
  • SAN DIEGO, May 08, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that the Company’s management will participate in a fireside chat and one-on-one investor meetings at the Citizens JMP Life Sciences Conference, to be held in New York, NY May 13-14, 2024.

BioAtla to Announce First Quarter 2024 Financial Results and Provide Business Highlights on May 14, 2024

Retrieved on: 
Mardi, mai 7, 2024
News, Press release, Therapy, Webcast, SAN, CAB, Conditional

SAN DIEGO, May 07, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that it plans to host a conference call and webcast on Tuesday, May 14, 2024 at 4:30 p.m.

Key Points: 
  • SAN DIEGO, May 07, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that it plans to host a conference call and webcast on Tuesday, May 14, 2024 at 4:30 p.m.
  • ET to discuss its financial results for the first quarter ended March 31, 2024 and provide business highlights.
  • The press release with the financial results will be accessible prior to the conference call through “ News Releases ” in the News & Events section of the company’s website.
  • A replay of the call will also be available through “ Events & Presentations ” in the Investors section of the company’s website.

BioAtla Announces FDA Clearance of Investigational New Drug Application for BA3361, a CAB-Nectin-4 Antibody Drug Conjugate for the Treatment of Multiple Tumors

Retrieved on: 
Lundi, mai 6, 2024
FDA, Immortalised cell line, CAB, Food, Brentuximab vedotin, IND, Therapy, ADC, Therapeutic index, Conditional, Serum, Toxicity, Nextgen, SAN, Pharmaceutical industry

ADC is a promising treatment modality with broad applicability across multiple tumor indications.

Key Points: 
  • ADC is a promising treatment modality with broad applicability across multiple tumor indications.
  • The CAB technology is designed to eliminate or reduce both on-target, off-tumor and off-target, off-tumor toxicities.
  • At the AACR Annual Meeting in April 2024, data showed differentiated anti-Nectin-4-ADC via in vitro and in vivo characterization of its novel next-generation carbohydrate linker system.
  • The NextGen linker system helped eliminate off-target, off-tumor toxicity with substantially improved serum stability and increased hydophilicity thereby improving potency.

Phoenix Children's Unveils "Wonder And Wander," a 407-Foot Mural to Advance Hope and Healing for Patient Families

Retrieved on: 
Mercredi, mai 1, 2024
Pixart, Phoenix Children's Hospital, Hope, Hospital, CAB, Heart, Chairperson, Trauma, Tree, Patient, Child, Lenhardt, Hughes, Anxiety, Sibling

PHOENIX, May 1, 2024 /PRNewswire/ -- Phoenix Children's today unveiled a 407-foot commissioned mural that has transformed a heavily trafficked corridor into a captivating and exciting journey for children and their families.

Key Points: 
  • PHOENIX, May 1, 2024 /PRNewswire/ -- Phoenix Children's today unveiled a 407-foot commissioned mural that has transformed a heavily trafficked corridor into a captivating and exciting journey for children and their families.
  • The installation is a collaboration between Phoenix Children's and RxART , a nonprofit organization that aims to help children heal through the power of visual art.
  • Inspired by RxART's mission, Phoenix Children's Board Chair and RxART Board Member David Lenhardt worked closely with the organization to create an art installation at Phoenix Children's Hospital – Thomas Campus.
  • "I am so grateful for RxART and especially for Shara, who put her heart and soul into creating the perfect piece for Phoenix Children's and the families we serve."

BioAtla Announces Upcoming Poster Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Retrieved on: 
Mercredi, avril 24, 2024
ASCO, CAB, Therapy, Society, SAN, Nivolumab, Conditional, Pharmaceutical industry

SAN DIEGO, April 24, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced a poster presentation at the upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting to be held virtually and at the McCormick Place Convention Center in Chicago, Illinois from May 31–June 4, 2024.

Key Points: 
  • SAN DIEGO, April 24, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced a poster presentation at the upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting to be held virtually and at the McCormick Place Convention Center in Chicago, Illinois from May 31–June 4, 2024.
  • Phase 1 study of BA3071, an anti-CTLA-4 conditionally active biologic, in combination with nivolumab in advanced solid tumors

Sevco Security Announced the Launch of a Customer Advisory Board

Retrieved on: 
Jeudi, avril 11, 2024
Software, Technology, Security, Internet, Learning, Argo Group, Risk, CAB, Customer advisory council, Intelligence, Environment, SVP, NSA, Intuit, Enterprise, AWS, Organization, Risk management

Sevco Security , the cloud-native Cyber Asset Attack Surface Management (CAASM) platform that delivers the industry’s most accurate, continuously updated security asset inventory to better protect organizations, today announced the launch of its inaugural Customer Advisory Board (CAB).

Key Points: 
  • Sevco Security , the cloud-native Cyber Asset Attack Surface Management (CAASM) platform that delivers the industry’s most accurate, continuously updated security asset inventory to better protect organizations, today announced the launch of its inaugural Customer Advisory Board (CAB).
  • “We have seen a tremendous benefit in bringing these industry experts together and learning from them each day,” said Brian Contos, Chief Strategy Officer at Sevco.
  • By pulling in more data on users, software, and vulnerabilities in customer environments, Sevco is able to provide deeper context on the risks and business impacts of the assets security teams are charged with protecting.
  • My team can then leverage this knowledge to quickly make informed decisions to protect both our organization and customers.”
    Some of Sevco’s Customer Advisory Board members include:
    Albert Attias, Senior Director of Enterprise Security, Workday
    Brandon Pinzon, SVP and Chief Security Officer, Argo Group
    To learn more about Sevco’s Customer Advisory Board and its current members, please visit: sevcosecurity.com/about-us/

BioAtla Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Progress

Retrieved on: 
Mardi, mars 26, 2024
Research, AXL, Head, Congress, NSCLC, SAN, Patient, Webcast, Observation, G&A, Peripheral neuropathy, CAB, Melanoma, D&O, Sarcoma, CD3, AACR, DLT, Conditional, ESMO, SITC, Therapy, ADC, Annual general meeting, SCCHN, Pharmaceutical industry

General and administrative (G&A) expenses were $5.9 million for the quarter ended December 31, 2023 compared to $6.7 million for the same quarter in 2022.

Key Points: 
  • General and administrative (G&A) expenses were $5.9 million for the quarter ended December 31, 2023 compared to $6.7 million for the same quarter in 2022.
  • Net loss for the quarter ended December 31, 2023 was $26.9 million compared to a net loss of $27.6 million for the same quarter in 2022.
  • Cash used for the quarter ended December 31, 2023 was $29.8 million.
  • Cash and cash equivalents as of December 31, 2023 were $111.5 million, compared to $215.5 million as of December 31, 2022.

Aviceda Therapeutics Announces Formation of Renowned European Clinical Advisory Board

Retrieved on: 
Lundi, avril 8, 2024
Technology, Research, Nanotechnology, Clinical Trials, Biotechnology, Health, Pharmaceutical, Optical, Science, Faculty, Medical University of Vienna, Part, Patient, Queen's University, Optometry, Queen's University Belfast, CAB, MD, Royal Victoria Hospital, Laborie (company), Medical school, Therapy, Retina, Safety, AMD, Geographic atrophy, Pharmaceutical industry

Aviceda Therapeutics , a private clinical-stage biotech company focused on developing next-generation immunomodulators by harnessing the power of glycobiology to alleviate chronic, non-resolving inflammation, announced today the formation of its European Clinical Advisory Board (CAB) made up of top internationally recognized thought leaders in retina to provide strategic consultation on the company’s clinical development of its lead asset, AVD-104, for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD).

Key Points: 
  • Aviceda Therapeutics , a private clinical-stage biotech company focused on developing next-generation immunomodulators by harnessing the power of glycobiology to alleviate chronic, non-resolving inflammation, announced today the formation of its European Clinical Advisory Board (CAB) made up of top internationally recognized thought leaders in retina to provide strategic consultation on the company’s clinical development of its lead asset, AVD-104, for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD).
  • The Company also announced that Tarek S. Hassan, MD will serve as Chair of the European and US CABs.
  • “We are excited that results from Part 1 of the US Phase 2/3 SIGLEC trial demonstrated functional and anatomic improvement in eyes with GA secondary to AMD after a single injection of AVD-104,” said Mohamed Genead, M.D., Aviceda’s Co-founder and CEO.
  • “With the contributions and support of this esteemed panel—and with Dr. Hassan as its chair—we look forward to bringing our clinical efforts to Europe later this year.”

BioAtla to Announce Fourth Quarter and Full-Year 2023 Financial Results and Provide Business Highlights on March 26, 2024

Retrieved on: 
Mardi, mars 19, 2024
Webcast, Therapy, SAN, News, Conditional, Press release, CAB

SAN DIEGO, March 19, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that it plans to host a conference call and webcast on Tuesday, March 26, 2024 at 4:30 p.m.

Key Points: 
  • SAN DIEGO, March 19, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that it plans to host a conference call and webcast on Tuesday, March 26, 2024 at 4:30 p.m.
  • ET to discuss its financial results for the fourth quarter and full-year ended December 31, 2023 and provide business highlights.
  • The press release with the financial results will be accessible prior to the conference call through “ News Releases ” in the News & Events section of the company’s website.
  • A replay of the call will also be available through “ Events & Presentations ” in the Investors section of the company’s website.

Stratasys Establishes New Customer Advisory Board to Drive Collaboration and Innovation in Additive Manufacturing

Retrieved on: 
Mercredi, mars 27, 2024
Electronic Design Automation, Engineering, Chemicals, Plastics, Technology, Manufacturing, Software, TE Connectivity, Manufacturing engineering, Learning, LTD, School, Toyota Motor North America, Research, 3D, University, Human, CAB, Senior, Industrial, 3D printing, Stratasys, Customer advisory council, Advanced technology, NIAR

Stratasys Ltd ., a leader in polymer 3D printing solutions, is excited to announce the launch of a new Industrial Customer Advisory Board (CAB).

Key Points: 
  • Stratasys Ltd ., a leader in polymer 3D printing solutions, is excited to announce the launch of a new Industrial Customer Advisory Board (CAB).
  • The CAB will provide the customer with added voice and insight as Stratasys continues to drive innovation in the additive manufacturing industry.
  • The 12-member Industrial Customer Advisory Board includes leaders from market leading manufacturers across Aerospace, Automotive, and Industrial Manufacturing, as well as institutions of research and higher learning.
  • Aligned with senior Stratasys leadership, the Customer Advisory Board provides input on requirements for scalable manufacturing applications and specific initiatives that focus on quality and reliability; characterization data; and alignment on an impactful sustainability strategy.